BostonGene and Unilever Partner to Apply AI and Multiomics Research to Support Consumer Innovation

Core Insights - BostonGene and Unilever have formed a strategic partnership to leverage AI and multiomics research for consumer innovation, aiming to inspire the next generation of science-based product development [1] - The collaboration will utilize BostonGene's advanced AI capabilities and omnimodal data integration alongside Unilever's scientific expertise to explore biological differences and generate actionable insights for product innovation [1] Company Overview - BostonGene specializes in AI-driven solutions for tumor and immune biology, integrating genomic, transcriptomic, and immune data with clinical outcomes to enhance drug development and patient care [1] - Unilever is a leading global supplier of consumer goods, with sales of €50.5 billion in 2025 and products used by 3.7 billion people daily [1] Partnership Objectives - The partnership aims to apply advanced AI and multiomics approaches to uncover insights that will drive innovative product development for Unilever's consumer base [1] - Unilever's investment in cutting-edge science and technology is intended to maintain its competitive edge in scientific innovation [1] Future Implications - The collaboration is expected to extend BostonGene's foundation model beyond oncology into broader areas of human biology, potentially accelerating discoveries that influence consumer-focused science [1]